CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01502410
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:53.387423+00:00
Published At: 2015-05-15T00:00:00+00:00
Record Updated At: 2018-06-26
Results Posted At: 2015-05-15
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Childhood Hepatocellular Carcinoma", "Papillary Thyroid Cancer", "Previously Treated Childhood Rhabdomyosarcoma", "Recurrent Childhood Liver Cancer", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Thyroid Cancer", "Recurrent Wilms Tumor and Other Childhood Kidney Tumors"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2018-06-26"
protocolSection.identificationModule.nctId: "NCT01502410"
protocolSection.identificationModule.officialTitle: "A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2015-05-15"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.